Wang Yuan, Yan Feng, Zhang Wenjing, Pang Shu, Jiang Fan
Department of Physiology and Pathophysiology, School of Basic Medicine, Shandong University, Jinan, China.
Department of Emergency, Qilu Hospital, Shandong University, Jinan, China.
J Cardiovasc Pharmacol. 2018 Feb;71(2):59-64. doi: 10.1097/FJC.0000000000000530.
Protein tyrosine phosphatase-1B (PTP1B) is an important negative regulator of insulin receptor- and vascular endothelial growth factor receptor-dependent signalings in endothelial cells. Genetic or pharmacological inhibition of PTP1B has been shown to enhance endothelial cell proliferation and migration and increase nitric oxide production. In vivo, inhibiting PTP1B can reverse endothelial dysfunction, promote angiogenesis, and accelerate wound healing. Intense research is currently continuing in an effort to discover novel selective PTP1B inhibitors, primarily for treating insulin resistance. We propose that these drugs may also represent a new horizon for boosting the regenerative capacities of endothelial cells.
蛋白酪氨酸磷酸酶-1B（PTP1B）是内皮细胞中胰岛素受体和血管内皮生长因子受体依赖性信号传导的重要负调节因子。已表明，对PTP1B进行基因或药理学抑制可增强内皮细胞的增殖和迁移，并增加一氧化氮的产生。在体内，抑制PTP1B可逆转内皮功能障碍、促进血管生成并加速伤口愈合。目前正在进行深入研究，以发现新型选择性PTP1B抑制剂，主要用于治疗胰岛素抵抗。我们认为，这些药物可能也为提高内皮细胞的再生能力开辟了新前景。
